CAR-T therapy cost: list prices, total episode cost, and what Medicare pays

CAR-T cell therapy is one of the most expensive single-administration treatments in modern medicine. The drug itself has a list price in the hundreds of thousands of dollars. Hospitalization for administration and monitoring typically adds another few hundred thousand dollars, bringing total episode cost to roughly $500,000 to $1,000,000 per patient. Medicare and commercial insurance cover CAR-T for approved indications, but coverage details, prior authorization requirements, and manufacturer access programs matter significantly for patient experience.

List prices

CAR-T therapies carry individual drug list prices in the range of approximately $373,000 to over $630,000 per single-administration dose. Specific list prices have risen over time since initial FDA approvals, so any figure should be confirmed against a current industry source.

Current approved CAR-T products for cancer indications include:

• Kymriah (tisagenlecleucel), Novartis. Indicated for relapsed or refractory B-cell acute lymphoblastic leukemia in children and young adults, and for relapsed or refractory large B-cell lymphoma in adults.
• Yescarta (axicabtagene ciloleucel), Kite / Gilead. Indicated for relapsed or refractory large B-cell lymphoma in adults.
• Breyanzi (lisocabtagene maraleucel), Bristol Myers Squibb. Indicated for relapsed or refractory large B-cell lymphoma.
• Tecartus (brexucabtagene autoleucel), Kite / Gilead. Indicated for mantle cell lymphoma and adult acute lymphoblastic leukemia.
• Abecma (idecabtagene vicleucel), Bristol Myers Squibb. Indicated for relapsed or refractory multiple myeloma.
• Carvykti (ciltacabtagene autoleucel), Johnson & Johnson / Legend Biotech. Indicated for relapsed or refractory multiple myeloma.

Total episode cost

List price is only part of the total bill. A CAR-T treatment episode typically includes:

• Leukapheresis (collection of the patient’s T cells)
• Lymphodepleting chemotherapy before CAR-T infusion
• The CAR-T infusion itself
• Inpatient hospitalization, often for two or more weeks given risk of cytokine release syndrome and neurotoxicity
• ICU-level care if complications occur
• Drug therapy for managing complications (tocilizumab, corticosteroids)

Total episode cost including drug, hospitalization, and related services commonly exceeds $500,000 and can reach $1,000,000 or more for patients requiring ICU-level care.

Medicare coverage

CMS has issued a National Coverage Determination for CAR-T therapy for FDA-approved indications. Medicare covers CAR-T for approved uses subject to the applicable clinical criteria.

For Medicare beneficiaries:

• CAR-T is typically administered during an inpatient stay and paid under Part A
• Hospital cost-sharing follows standard Part A rules (the deductible, then $0 coinsurance for days 1 to 60)
• Patients with Medigap policies have most Part A cost-sharing covered
• Medicare Advantage plans cover CAR-T for approved indications, with the plan’s annual out-of-pocket maximum applying

The New Technology Add-On Payment (NTAP) program affects hospital reimbursement for CAR-T, which has been a subject of ongoing policy attention because the drug price has historically been higher than standard hospital DRG reimbursement amounts.

Commercial insurance coverage

Most commercial insurance plans cover CAR-T for FDA-approved indications. Patients can expect:

• Prior authorization. Virtually always required. The treating center’s team handles this.
• Treatment at an approved center. CAR-T is administered only at certified centers that have completed the manufacturer’s REMS (Risk Evaluation and Mitigation Strategy) training. Not every hospital is approved; verify before starting.
• Annual out-of-pocket maximum applies. For ACA-compliant plans, this is $9,450 per individual or $18,900 per family for 2024.

Manufacturer patient access programs

Each CAR-T manufacturer operates patient access services:

• Kymriah Cares (Novartis). Benefits investigation, financial-assistance navigation, and patient support.
• Kite Konnect (Gilead, for Yescarta and Tecartus). Case management, insurance support, and travel assistance.
• Breyanzi Patient Support (BMS). Financial assistance referrals, including referrals to disease-foundation copay programs.
• Abecma Patient Support (BMS). Similar structure to Breyanzi program.

Patients with commercial insurance may qualify for copay assistance through the manufacturer’s program, subject to eligibility rules. Medicare beneficiaries cannot use manufacturer copay cards due to federal anti-kickback rules but can apply for free drug through the manufacturer’s patient assistance program if income-eligible.

Travel and lodging

CAR-T is administered only at certified centers, and patients and a caregiver typically need to stay near the center for a minimum of four weeks post-infusion. Travel and lodging costs are often significant:

• Some manufacturer programs include travel or lodging assistance
• Disease foundations (Blood Cancer United, CancerCare, Leukemia Research Foundation) offer travel grants
• Hope Lodge (American Cancer Society) provides free lodging near some treatment centers
• Joe’s House lists discounted lodging near hospitals

Who should consider CAR-T

CAR-T is indicated for specific relapsed or refractory cancers where prior therapies have not produced durable remission. Your oncologist will determine if CAR-T is appropriate for your disease and stage. If you are considering CAR-T, a second opinion at a center experienced in CAR-T administration is often valuable. See how to get a second opinion without a referral and the second opinion hub.

Next

• Immunotherapy cost: the broader checkpoint-inhibitor cost picture
• Does Medicare cover cancer treatment?
• Financial assistance for cancer patients
• Clinical trial phases explained